Marcellin Patrick
Service d'Hépatologie, AP-HP and INSERM U773, Centre de Recherche Biologique Bichat-Beaujon CRB3, Université Denis Diderot-Paris 7, Hôpital Beaujon, Clichy, France.
Liver Int. 2009 Jan;29 Suppl 1:1-8. doi: 10.1111/j.1478-3231.2008.01947.x.
Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are among the most frequent viral infections in humans, and represent a major global public health problem. HBV- and HCV-related chronic hepatitis are the main causes of cirrhosis and hepatocellular carcinoma (HCC) that are responsible for a high rate of morbidity and mortality. End-stage HBV- and HCV-related liver disease and HCC are the main causes of liver transplantation. In the last few years, knowledge of the epidemiology and the natural history of HBV and HCV infection has markedly improved. Furthermore, considerable progress has been made in the efficacy of therapy. New drugs and new therapeutic strategies that are currently under evaluation could further improve the efficacy of therapy in the near future.
乙型肝炎病毒（HBV）和丙型肝炎病毒（HCV）感染是人类最常见的病毒感染之一，也是一个重大的全球公共卫生问题。HBV和HCV相关的慢性肝炎是肝硬化和肝细胞癌（HCC）的主要病因，导致了高发病率和死亡率。终末期HBV和HCV相关肝病及HCC是肝移植的主要原因。在过去几年中，对HBV和HCV感染的流行病学及自然史的认识有了显著提高。此外，治疗效果也取得了相当大的进展。目前正在评估的新药和新治疗策略可能在不久的将来进一步提高治疗效果。
